Company intelligence / Profile preview

Admetsys

Boston, Massachusetts, United Statesadmetsys.com ↗

Ownership: Private
Development stage: Other

Overview

Admetsys' PrecisionOne™ automated glucose control and blood diagnostics platform demonstrated superior performance to standard care in three U.S. clinical trials, achieving higher time-in-range for blood glucose levels and reducing hypoglycemic events to zero. The system also enables early sepsis detection via continuous lactate monitoring. The product has received FDA Breakthrough Device Designation. Key outcomes include reduced mortality by up to 34%, shortened ICU stays by up to two days, and significant per-patient cost savings. Commercial launch pending regulatory clearance.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: DeviceClinical automation system (not a drug/biologic; hardware/software medical device)
Industry: Metabolite Diagnostics

Partnerships

Not specifically disclosed as of June 2025.

Beyond the preview

Go deeper on Admetsys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Admetsys.

Explore the full profile